<DOC>
	<DOCNO>NCT00758849</DOCNO>
	<brief_summary>The purpose study determine whether Fipamezole effective treatment orthostatic hypotension relate symptom multiple system atrophy Parkinson 's disease .</brief_summary>
	<brief_title>Fipamezole Neurogenic Orthostatic Hypotension</brief_title>
	<detailed_description>This study exploratory , proof concept , randomise , placebo-controlled , double-blind , multiple crossover study , open-label active run-in phase , patient multiple system atrophy ( MSA ) Parkinson 's disease ( PD ) concomitantly treat fludrocortisone antiparkinsonian medication . Three site France one site Portugal participate study . During open-label active run-in phase , tolerate dose-escalation regimen ( either escalate 30 90 60 mg tid , escalation fix dose 30 mg tid ) establish patient . Once tolerated treatment regimen establish , patient randomise double-blind crossover treatment . Fipamezole match placebo tablet compare 3 crossover block , block consist total 28 day : 12 day fipamezole 12 day placebo random order , separate two day washout . The patient randomly assign one two possible treatment sequence ( fipamezole first follow placebo placebo first follow fipamezole ) . For efficacy assessment , patient blood pressure heart rate assess repeatedly lay still stand . Impact orthostatic hypotension clinical symptom assess subjective scale questionnaire . To explore potential positive negative impact fipamezole disease characteristic , MSA PD patient assess UMSARS UPDRS scale , respectively . Finally , study include investigator patient assessments CGI-I PGI-I scale clinical condition general . Fipamezole Fipamezole new antagonist pre-synaptic adrenergic alpha-2 receptor investigate potential use adjunctive therapy PD . Adrenergic alpha-2 receptor inhibit noradrenaline neurotransmitter release nerve terminal tonic manner , therefore antagonism receptor lead enhance neurotransmitter release . Alpha-2 receptor locate widely body , central nervous system ( CNS ) periphery . Pharmacological study suggest either central peripheral autonomic nervous system involve autonomic failure orthostatic hypotension MSA PD . Neurogenic orthostatic hypotension disease result decrease delivery sympathetic neurotransmitter noradrenaline ( hormonal adrenaline ) vascular adrenergic receptor , either blunt CNS control impaired function postganglionic sympathetic neuron . Fipamezole expect increase noradrenergic ( adrenergic ) turnover specific area brain periphery MSA PD alleviate symptom related fall BP orthostatism .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Hypotension</mesh_term>
	<mesh_term>Multiple System Atrophy</mesh_term>
	<mesh_term>Shy-Drager Syndrome</mesh_term>
	<mesh_term>Hypotension , Orthostatic</mesh_term>
	<criteria>Male female patient ≥ 30 &lt; 80 year age intact oral mucosa screen Diagnosis MSA diagnosis idiopathic PD Hoehn Yahr stag 1 4 'Off ' period NOH : reproducible fall SBP ≥20 mmHg and/or fall DBP ≥10 mmHg 15 min supine rest 3 min stand ( symptomatic hypotension &lt; 3 min stand ) For patient take antiparkinsonian medication : stable daily dose least 1 month For patient take fludrocortisone : stable dose least 2 month Demonstrated ability comprehend , give informed consent comply study procedure ( BP selfmonitoring , completion patient diary selfassessment rating scale ) Other clinically significant condition apart typically associate MSA PD SBP ≥200 mmHg DBP ≥120 mmHg 15 min supine rest quiet environment Clinically significant abnormality ECG MiniMental State Examination ( MMSE ) score &lt; 24 Intake prohibit concomitant medication midodrine , intake medication associate vasodilatation induction liver enzymes ; neuroleptic ; certain drug know substantially metabolize follow cytochrome P450 isoenzymes : 1A2 , 2B6 , 2C19 , 2C9 , 2D6 2E1 ; drug treatment orthostatic hypotension ( include offlabel use ) , nonsteroidal antiinflammatory drug , beta blocker , somatostatin Use St. John 's Wort Ginkgo Biloba within 48 h prior inclusion course study Intake investigational drug within 30 day prior screen</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>NOH</keyword>
	<keyword>Orthostatic hypotension</keyword>
	<keyword>PAF</keyword>
	<keyword>MSA</keyword>
	<keyword>Shy-Drager syndrome</keyword>
	<keyword>Olivopontocerebellar atrophy</keyword>
	<keyword>Striatonigral degeneration</keyword>
	<keyword>Autonomic Failure</keyword>
	<keyword>Parkinson</keyword>
	<keyword>Fipamezole</keyword>
	<keyword>JP-1730</keyword>
</DOC>